课题基金 / 基金详情

PHASE I STUDY OF TEMOZOLOMIDE IN TREATMENT OF ANAPLASTIC ASTROCYTOMA

PHASE I STUDY OF TEMOZOLOMIDE IN TREATMENT OF ANAPLASTIC ASTROCYTOMA
替莫唑胺治疗间变性星形细胞瘤的 I 期研究
批准号：
6246373
负责人：
MICHAEL D PRADOS
金额：
$4.89万
依托单位：
UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
依托单位国家：
美国
项目类别：
财政年份：
1997
资助国家：
美国
项目状态：
已结题
起止时间：
1997-02-04 至 1997-11-30
来源：
https://reporter.nih.gov/project-details/6246373
关键词：
antineoplastics blood chemistry clinical research clinical trial phase I drug administration rate /duration drug screening /evaluation glioblastoma multiforme human subject human therapy evaluation neoplasm /cancer chemotherapy neoplasm /cancer relapse /recurrence oral administration pharmacokinetics

项目摘要

项目成果

MICHAEL D PRADOS的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Temozolomide will be evaluated for safety, efficacy, maximum tolerated dose and pharmacokinetics in patients with Anaplastic Astrocytoma experiencing first relapse. Temozolomide will be administered orally 1/day x 5 days every 28 days. Pts will fast 4 hrs before and 2 hrs after each dose. Pharmacokinetics will be drawn on Day 1 Cycle 1. All patients will be drawn at baseline (before dosing) and 4 times post- dosing.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
A PHASE I STUDY OF OSI-774 AND TEMOZOLOMIDE FOR THE TREATMENT OF GLIOMAS
NABTC 01-08: PHASE II TRIAL OF STI571 (NSC 716051) IN RECURRENT MENINGIOMA
ZD1839 FOR MALIGNANT ASTROCYTOMA OR GLIOBLASTOMA AND MENINGIOMA
A PHASE II TRIAL OF POLY ICLC IN PATIENTS WITH RECURRENT ANAPLASTIC GLIOMA
海外基金